CAJ | 학술논문

目的检测Her-2/neu蛋白和雄激素受体(androgen receptor,AR)在前列腺癌组织中的表达情况,探讨其在前列腺癌发生发展中的意义.方法构建前列腺病变的组织芯片,其中包括前列腺癌107例(Gleason评分6分29例,7分20例,8分46例,9分12例),良性前列腺组织42例;采用EnVsion两步法进行Her-2/neu蛋白和AR的免疫组织化学染色,分析其在前列腺癌及良性前列腺组织中的差异;从免疫组织化学染色强度及阳性细胞数两个方面评价蛋白表达情况,分析其与前列腺癌Gleason评分的关系.结果 Her-2/neu蛋白在前列腺癌组织中的阳性表达率为43.9%,高于在良性前列腺组织中的阳性表达率(14.3%)(x2=11.562,P=0.009),其阳性表达强度前列腺癌高于良性前列腺组织(x2=11.764,P=0.008).在不同Gleason评分组中,Her-2/neu蛋白的阳性表达强度差异有统计学意义(x2=20.512,P=0.015),且与Gleason评分呈正相关(r=0.269,P=0.005).前列腺癌组织AR阳性表达率(67%)高于良性前列腺组织(50%)(x2=3.843,P=0.050),但其阳性表达强度在前列腺癌及良性前列腺组织中的差异无统计学意义(x2=4.318,P=0.229).在不同Gleason评分组中AR的阳性表达强度差异无统计学意义(x2=13.385,P=0.146),与Gleason评分无相关性(r=-0.065,P=0.505).前列腺癌组织中Her-2/neu蛋白和AR的阳性表达强度无相关性(r=-0.115,P=0.237).结论Her-2/neu蛋白在前列腺癌中的高表达提示其可能在前列腺癌发生中起一定作用.Her-2/neu蛋白的阳性表达强度与Gleason评分呈正相关,提示Her-2/neu蛋白与前列腺癌的预后有一定的相关性.
목적 검측Her-2/neu단백화웅격소수체(androgen receptor,AR)재전렬선암조직중적표체정황,탐토기재전렬선암발생발전중적의의.방법 구건전렬선병변적조직심편,기중포괄전렬선암107례(Gleason평분6분29례,7분20례,8분46례,9분12례),량성전렬선조직42례;채용EnVsion량보법진행Her-2/neu단백화AR적면역조직화학염색,분석기재전렬선암급량성전렬선조직중적차이;종면역조직화학염색강도급양성세포수량개방면평개단백표체정황,분석기여전렬선암Gleason평분적관계.결과 Her-2/neu단백재전렬선암조직중적양성표체솔위43.9%,고우재량성전렬선조직중적양성표체솔(14.3%)(x2=11.562,P=0.009),기양성표체강도전렬선암고우량성전렬선조직(x2=11.764,P=0.008).재불동Gleason평분조중,Her-2/neu단백적양성표체강도차이유통계학의의(x2=20.512,P=0.015),차여Gleason평분정정상관(r=0.269,P=0.005).전렬선암조직AR양성표체솔(67%)고우량성전렬선조직(50%)(x2=3.843,P=0.050),단기양성표체강도재전렬선암급량성전렬선조직중적차이무통계학의의(x2=4.318,P=0.229).재불동Gleason평분조중AR적양성표체강도차이무통계학의의(x2=13.385,P=0.146),여Gleason평분무상관성(r=-0.065,P=0.505).전렬선암조직중Her-2/neu단백화AR적양성표체강도무상관성(r=-0.115,P=0.237).결론Her-2/neu단백재전렬선암중적고표체제시기가능재전렬선암발생중기일정작용.Her-2/neu단백적양성표체강도여Gleason평분정정상관,제시Her-2/neu단백여전렬선암적예후유일정적상관성.
Objective To observe the expression of Her-2/neu protein and androgen receptor (AR) in human prostate cancer and to evaluate their significances in the progression of prostate cancer. Methods The Her-2/neu protein and AR immunohistochemical stain were carried out in human prostate tissue microarray that consisted of prostate cancer (107 cases) and benign prostate tissue (42 cases). The prostate cancer cases were divided into 4 groups: group one (Gleason score 6),group two (Gleasonscore 7), group three (Gleasonscore 8) and group four (Gleasonscore 9) according to the Gleason score. The immunostains immunohistochemical stain were interpreted in two aspects of the staining intensity and the percentage of positive cells. The significance and relationships between the expression of Her-2/neu protein and AR in prostate cancer and benign prostate tissue (BPT) and the grouping of different Gleason scores of prostate cancer were then evaluated. Results The positive expression rate of Her-2/neu protein was significantly higher in prostate cancer tissue than in BPT [43.9%(47/107) vs. 14.3%(6/42), x2=11.562, P=0.009], and the positive expression intensity of Her-2/neu immunoreactivity was also higher (x2= 11.764, P=0.008). There were significant differences in positive expression intensity of Her-2/neu immunoreactivity among the different Gleason scores groups (x2 = 20. 512, P = 0. 015), and the expression intensity was significantly positively correlated with Gleason scores ( r= 0. 269, P = 0. 005). There was significant difference in AR immunoreactivity between in prostate cancer (67 %, 72/107) and in BPT (50 %, 21/42, x2 =3. 843, P=0. 050). Among prostate cancer cases, the positive expression intensity of AR was not significantly different among groups 1 through 4 (x2 = 4. 318, P = 0. 229), and was not significantly correlated with Gleason scores ( r = - 0. 065, P = 0. 505 ). Moreover, the positive expression intensity of Her-2/neu protein was not significantly correlated with that of AR (r = -0. 115, P=0. 237). Conclusions Overexpression of Her-2/neu protein in human prostate cancer tissue suggests that Her-2/neu may have some role in prostate tumorigenesis. Her-2/neu protein expression is positively correlated with Gleason score in prostate cancer, which suggests that Her-2/neu may be a potential prognostic predictor of prostate cancer.